Natural History of Atrial Fibrillation-Induced Tricuspid Valve Remodeling in the Absence of Significant Tricuspid Regurgitation: A Three-Dimensional Echocardiographic Study (TRICUSPID-AF)
Status: Recruiting
Location: See location...
Study Type: Observational
SUMMARY
This is a prospective, observational, multicenter study aimed at characterizing tricuspid valve remodeling in patients with atrial fibrillation (AF) without significant tricuspid regurgitation (TR), in relation to AF burden progression.
Eligibility
Participation Requirements
Sex: All
Minimum Age: 18
Healthy Volunteers: t
View:
• Consecutive patients with atrial fibrillation (paroxysmal or persistent) undergoing transthoracic echocardiography (TTE) prior to AF ablation with acquisition of a 3D TV dataset.
‣ Eligible for enrollment in the control group will be:
⁃ all consecutive patients with structurally normal hearts and no history of AF or;
⁃ moderate atrial functional tricuspid regurgitation and AF, in the absence of significant left-sided valvular disease or prior valvular surgery.
Locations
Other Locations
Italy
Centro Cardiologico Monzino; IRCCS
RECRUITING
Milan
Time Frame
Start Date: 2026-05-04
Estimated Completion Date: 2027-05-31
Participants
Target number of participants: 66
Treatments
Prospective Cohort
Participants with paroxysmal or persistent atrial fibrillation undergoing clinically indicated transthoracic echocardiography (TTE) prior to catheter ablation with acquisition of a three-dimensional (3D) tricuspid valve dataset. Participants will undergo repeat transthoracic echocardiography at 12-month follow-up and rhythm monitoring with Holter ECG according to standard clinical practice. No study-specific interventions are planned.
Control group
The study cohort will be compared with control populations undergoing clinically indicated transthoracic echocardiography:~1. subjects with structurally normal hearts and no history of atrial fibrillation;~2. patients with atrial fibrillation and ≥ moderate atrial functional tricuspid regurgitation, in the absence of significant left-sided valvular disease or prior valvular surgery.
Related Therapeutic Areas
Sponsors
Leads: Centro Cardiologico Monzino
Collaborators: Istituto Clinico Humanitas